|Date||5 December 2020 – present|
|Cause||COVID-19 pandemic in Russia|
|Target||Immunization against COVID-19|
|Participants||52,943,693 people have received at least one dose (25 October 2021) |
46,768,678 people have been fully vaccinated (25 October 2021)
|Outcome||36.3% of the Russian population has received at least one dose of a vaccine|
The COVID-19 vaccination campaign in Russia is an ongoing mass immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. Mass vaccinations began in December 2020, starting with primarily doctors, medical workers and teachers, and in January 2021, this was extended to the entire population.
As of 25 October 2021, 52.9 million people have received at least one dose, with 46.8 million people fully vaccinated.
On 11 August 2020, President Putin said in a meeting that the Sputnik V vaccine (registered as Gam-COVID-Vac) developed by the Gamaleya Research Institute of Epidemiology and Microbiology was the first vaccine against the coronavirus to be registered. He said that one of his daughters was vaccinated.The previous day, the Association of Clinical Research Organisations, a union of pharmaceutical companies in Russia, urged the head of the Ministry of Health to delay the registration due to incomplete testing. The head of the Russian Direct Investment Fund (RDIF) stated that 20 countries had requested in total 1 billion doses of the vaccine, nicknamed Sputnik V. On August 20 registration was called "conditional" with final registration depends on results of Phase 3 trial, such registration is limited and allowed by Decree 441 for medicines in emergency situations.
On 8 September 2020, the health ministry's press service said that the first batches of the vaccine developed by the Gamaleya Centre had entered civilian circulation.
On 14 October 2020, President Vladimir Putin announced that the EpiVacCorona vaccine was approved.Registration is limited ("on conditions") and regulated by Decree 441 for emergency use.
On 20 February 2021, President Vladimir Putin announced that the CoviVac vaccine was approved.Registration is limited ("on conditions") too and regulated by Decree 441 for emergency situation.
On 6 May 2021, Sputnik Light vaccine was approved.
|Vaccine||Emergency Use Approval||Deployment||Final Approval|
|Sputnik V||10 August 2020||27 November 2020||No|
|EpiVacCorona||14 October 2020||18 January 2021||No|
|CoviVac||20 February 2021||25 March 2021||No|
|Sputnik Light||6 May 2021||Not yet||No|
On 2 December 2020, President Putin ordered the start of mass vaccination of the population for the next week, starting with doctors, medical workers and teachers.On 5 December, vaccinations began in Moscow.
On 10 December 2020, Deputy Prime Minister Tatyana Golikova announced that approximately 6.9 million doses of the Sputnik V vaccine will enter civilian circulation in Russia before the end of February 2021. On December 15, the Ministry of Health announced the start of mass vaccination in all regions.
On 6 January 2021, the RDIF announced that 1 million people had been vaccinated with the Sputnik V vaccine. On January 10, 2021, the RDIF stated that over 1.5 million people had been vaccinated.
By 17 February 2021, 2.2 million people had received the first dose of the Sputnik V vaccine and another 1.7 million people had received both doses.
By 15 March 2021, over 3.5 million people had received both doses of the Sputnik V vaccine, according to the RDIF.
On 9 April 2021, Prime Minister Mikhail Mishustin said that less than half of those vaccinated were over the age of 60.
On 14 April 2021, Moscow Mayor Sergei Sobyanin said that around 820,000 Muscovites had been fully vaccinated, out of a population of 12 million. Sobyanin also said that Moscow was "fully supplied" with vaccines and urged Muscovites to get vaccinated. By 14 April, an estimated 9.5 million Russians had received at least one vaccine dose, with around 5.6 million having received both doses.
On 25 April 2021, Sobyanin announced that those over the age of 60 who get vaccinated would be eligible to receive a gift card worth 1,000 rubles to spend in shops, raised through contributions from businesses, in an effort to incentivize the vaccination campaign.
On 26 April 2021, 11.9 million people overall had received at least a first dose of a vaccine, representing 10% of the adult population.
On 21 May 2021, Mayor of Moscow Sobyanin decried low demand for vaccines, despite free and easy access to them since January. In a meeting, he said: "It's a shame that we have not had any restrictions on vaccinations for six months and we were the first in the world to launch a mass vaccination campaign... Unfortunately, we still have 9,000 Muscovites in hospitals with severe cases of coronavirus... People are still dying, yet don't want to get vaccinated". Sobyanin also stated that the percentage of people vaccinated in Moscow was less than in any other European city.
On 16 June 2021, Sobyanin announced that Moscow would introduce mandatory vaccinations for service workers in the city, following a surge in cases in the city. Business operating in service sectors would be required to have at least 60% of their workforce vaccinated with a first dose by 15 July, with both doses by 15 August.
On 22 June 2021, Sobyanin announced that, beginning 28 June, restaurants, bars and cafes in Moscow would be restricted to those who can show they have been vaccinated, had the virus confirmed within the last six months, or tested negative in the last three days.By 22 June, compulsory vaccinations were also decided in a number of other regions aside from Moscow and Moscow Oblast, including the city of St. Petersburg, the Sakha Republic, the Nenets Autonomous Okrug, the Leningrad, Tula, Kemerovo, Sakhalin and Tver oblasts, and Krasnodar Krai. Kremlin spokesman Dmitry Peskov also stated that discrimination against the unvaccinated was inevitable.
By 2 July 2021, compulsory vaccinations were introduced in a total of 24 federal subjects, with compulsory vaccinations planned to be introduced in Crimea and Murmansk Oblast.
Public scepticism of being vaccinated remains high.A poll by the Levada Center released on 1 March 2021 found that 62% of Russian respondents did not want to receive the country's Sputnik V vaccine, with younger respondents being more reluctant. Another poll by the Levada Center released on 12 May found that 62% of Russian respondents were not ready to get vaccinated with Sputnik V, with 75% of respondents aged 18-24 years old not ready compared to 47% for those over 55 years of age. A survey by the SuperJob.ru job portal published on 16 May found that 42% of Russian respondents would not get vaccinated under any circumstances. Public scepticism continues to exist despite Russian and Western sources detailing the positive efficacy of the vaccine. A study in 2017 indicated that anti-vaccine views had been present in Russia prior to the pandemic, which only increased after the pandemic emerged.
Serum Institute of India (SII) is an Indian biotechnology and biopharmaceuticals company. It is the world's largest manufacturer of vaccines located in the city of Pune, India and was founded by Cyrus Poonawalla in 1966. The company is a subsidiary of the holding company Poonawalla Investment and Industries.
The COVID-19 pandemic in Russia is part of the ongoing pandemic of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2. The virus was confirmed to have spread to Russia on 31 January 2020, when two Chinese citizens in Tyumen (Siberia) and Chita tested positive for the virus, with both cases being contained. Early prevention measures included restricting the border with China and extensive testing. The infection spread from Italy on 2 March, leading to additional measures such as cancelling events, closing schools, theatres, and museums, as well as shutting the border and declaring a non-working period which, after two extensions, lasted until 11 May 2020. By the end of March 2020, the vast majority of federal subjects, including Moscow, had imposed lockdowns. By 17 April 2020, cases had been confirmed in all federal subjects. At the beginning of September 2020, the number of COVID-19 cases in Russia reached a million. The number of COVID-19 cases in the country also reached two million on 19 November 2020, three million on 26 December 2020, four million on 10 February 2021, five million on 23 May 2021, six million on 20 July 2021 and seven million on 5 September 2021. At the end of 2020, there were nearly 3.2 million COVID-19 cases in Russia. On 3 April 2021, the number of COVID-19 deaths in the country reached 100,000. Several months later, on 22 September 2021, the number of COVID-19 deaths in Russia reached 200,000.
There are no confirmed cases of COVID-19 in Turkmenistan with the totalitarian government being proactive in censoring relevant information. It is however expected to have spread in the country unreported; specifics are difficult to ascertain and confirm in absence of independent media.
Sputnik V or Gam-COVID-Vac is an adenovirus viral vector vaccine for COVID-19 developed by the Gamaleya Research Institute of Epidemiology and Microbiology in Russia. It is the world's first registered combination vector vaccine for the prevention of COVID-19, having been registered on 11 August 2020 by the Russian Ministry of Health.
The Gamaleya Research Institute of Epidemiology and Microbiology, previously the N. F. Gamaleya Federal Research Center for Epidemiology & Microbiology, is a Russian medical-research institute within the Ministry of Health of the Russian Federation.
CoronaVac, also known as the Sinovac COVID-19 vaccine, is an inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech. It was Phase III clinical trialled in Brazil, Chile, Indonesia, the Philippines, and Turkey and relies on traditional technology similar to BBIBP-CorV and Covaxin, other inactivated-virus COVID-19 vaccines. CoronaVac does not need to be frozen and both the final product and the raw material for formulating CoronaVac can be transported refrigerated at 2–8 °C (36–46 °F), temperatures at which flu vaccines are kept.
The COVID-19 vaccination in Bulgaria is an immunization campaign currently taking place against SARS-CoV-2, the virus that is the cause of the COVID-19 disease. It began on 27 December 2020, in line with most other countries in the EU, and is in response to the ongoing pandemic in Bulgaria. The vaccination drive was affected by organizational and supply-related issues during the initial months while since the spring of 2021 vaccine hesitancy has contributed significantly to the country having the lowest rate of inoculations in the EU, with 20% of Bulgaria's adult citizens fully vaccinated by early September.
India began administration of COVID-19 vaccines on 16 January 2021. As of 27 October 2021, India has administered over 1.04 billion doses overall, including first and second doses of the currently-approved vaccines. In India, nearly half the eligible population has got at least one shot, and 19 per cent received both nine months after the vaccine rollout.
EpiVacCorona is a peptide-based vaccine against COVID-19 developed by the VECTOR center of Virology. It consists of three chemically synthesized peptides that are conjugated to a large carrier protein. This protein is a fusion product of a viral nucleocapsid protein and a bacterial MBP protein. The third phase of a clinical trial, which should show whether the vaccine is able to protect people from COVID-19 or not, was launched in November 2020 with more than three thousand participants.
The COVID-19 vaccination campaign in Albania is a mass immunization campaign that was put in place by the Albanian authorities in order to respond to the ongoing COVID-19 pandemic. It started on 11 January 2021.
R-Pharm is an international pharmaceutical company headquartered in Russia. It reached the headlines in 2020 following approval of its drug 'Coronavir' as a treatment in cases of mild to moderate COVID-19 infection. It was founded by Alexey Repik in 2001, but has had an increasingly international operations base since, with Japanese Corporation Mitsui & Co., Ltd. acquiring 10% of its shares in 2017.
On 29 January 2021, Algeria launched a coronavirus vaccination campaign, a day after receiving its first shipment of 50,000 doses of the Russia's Sputnik V vaccine. As of 6 June 2021, around 2.5 million doses have been administered. Algeria is currently vaccinating its population with both Sputnik V and Oxford-AstraZeneca vaccines.
QazCovid-in, commercially known as QazVac, is a COVID-19 vaccine developed by the Research Institute for Biological Safety Problems in Kazakhstan. QazCoVac-P is a second COVID-19 vaccine developed by the Kazakh Biosafety Research Institute and in clinical trials.
The COVID-19 vaccination in Vietnam is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in response to the ongoing pandemic in the country. Following the approval of the Oxford–AstraZeneca COVID-19 vaccine on 30 January 2021, vaccinations commenced on 8 March 2021, and will continue throughout the year with the goal of vaccinating 80% of the population by June 2022. The Sputnik V was later approved for use on 23 March 2021. Sinopharm COVID-19 vaccine was approved for emergency use on 4 June 2021, while Pfizer–BioNTech COVID-19 vaccine, Moderna COVID-19 vaccine and Janssen COVID-19 vaccine were approved on 12 June 2021, 29 June 2021, and 15 July 2021, respectively. Vietnam approved Abdala vaccine from Center for Genetic Engineering and Biotechnology on 18 September 2021.
Sputnik Light is a single dose COVID-19 vaccine developed by the Gamaleya Research Institute of Epidemiology and Microbiology. It consists of the first dose of the Sputnik V vaccine, which is based on the Ad26 vector, and it can be stored at a normal refrigerator temperature of 2–8 °C (36–46 °F). The institute says this version would be ideally suited for areas with acute outbreaks, allowing more people to be vaccinated quickly. It will also be used as a third (booster) dose for those who received Sputnik V at least 6 months earlier.
COVID-19 vaccination in Kazakhstan is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
The COVID-19 vaccination campaign in Ukraine is an ongoing mass immunization campaign for the COVID-19 pandemic in Ukraine.
Russia .. saying the vaccine approval was a “conditional registration certificate”
provisional approval was issued under conditions established by Government Decree 441
регистрация была выдана «на условиях», определенных постановлением правительства (№ 441)
This is a reckless and foolish decision. Mass vaccination with an improperly tested vaccine is unethical. Any problem with the Russian vaccination campaign would be disastrous both through its negative effects on health, but also because it would further set back the acceptance of vaccines in the population.